No abstract

No abstract

No abstract

Background: Molecular-genetic markers and remote results in osteosarcoma treatment. Methods: The diagnostic program of 173 patients with osteosarcoma included conventional measures. Immunohistochemistry (IHC) study was carried out on sections with paraffin blocks. Results: Achievement of complete morphological regression during chemotherapy was revealed in 13% of patients, among which 70.6% of patients had no expression of mutant p53 gene and expression of Ki-67 gene, and expression of bcl-2 gene was found in 80.0%. In 15.7% of patients after the use of the long-term regional endoarterial chemotherapy (LTREC)scheme, complete morphological regression was also observed, in 87.5% of these patients the mutant p53 gene was absent, in 90.0% of these patients expression of the bcl-2 gene was high, and in 80.0% of these the expression of the Ki-67 gene was not detected. The survival function of patients with OS calculated by the Kaplan-Meier method in association with the expression of oncomarkers allowed us to state that in the absence of expression of the mutant mtp53 gene and expression of the Ki-67 gene, the probability of survival of up to 3 years was 98% of patients, whereas in the presence of expression of these genes this period reach 85% of patients. Up to 5 years, 50% of patients with no expression of mtp53 and Ki-67 genes and 30% -40% with high expression are surviving. However, only patients from groups lacking mtp53 gene expression and Ki-67 gene have a probability of surviving to 15 years, such patients may be 15%. The inverse association of survival of patients was observed in the absence of expression of the gene bcl-2, the probability of survival of up to 3 years was in 90% of patients, whereas in the presence of expression of this gene this period reaches 98% of patients. Conclusions: Chromosomal instability (increased aberrations of chromosomes in peripheral blood lymphocytes in patients above 5%), the level of expression of biomarkers of apoptosis and proliferation (mtp53 þ, bcl-2-, Ki-67 þ) are prognostically unfavorable factors of early metastasis and the appearance of early relapses (from 6 to 9 months). Legal entity responsible for the study: The Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology of the Ministry of Health of the Republic of Uzbekistan. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest. 412P Comprehensive mRNA-based screen for tyrosine kinase fusions and a de novo alternative transcription initiation site in soft tissue sarcomas

No abstract